CO-EXPRESSION OF Gia PROTEIN AND Gi PROTEIN COUPLED RECEPTOR TO ENHANCE SIGNAL TRANSDUCTION RESPONSES

Abstract: A method for detecting compounds that bind to a Gi protein coupled receptor which comprises the steps of culturing a cell in a medium under conditions wherein Gia protein and a Gi protein coupled receptor are co-expressed, contacting the cell with a test compound, and assaying the cell for a cellular response to the compound, the response being an increase in the cytoplasmic calcium concentration, where the cell has been transfected with a gene encoding aGi protein coupled receptor and a gene coding for Gia protein capable of coupling to said Gi protein coupled receptor. Cells useful in such methods, and methods for making such cells, are also provided.

Description: CO-EXPRESSION OF G IA PROTEIN AND G I PROTEIN COUPLED RECEPTOR TO ENHANCE SIGNAL TRANSDUCTION RESPONSES FIELD OF THE INVENTION The invention relates to methods for rapidly assaying for agonism or antagonism of G ( protein coupled receptors and to cells which can serve as assay systems for evaluating such agonism or antagonism. The invention relates particularly to methods for rapidly assaying for agonist and antagonist compounds which bind to G; protein coupled receptors which stimulate intracellular calcium mobilization, such as the nociceptin receptor, and particularly chemokine receptors such as CCR3, CCR2, and the interleukin 8 receptor type B. BACKGROUND OF THE INVENTION G proteins (guanine nucleotide binding regulatory proteins) are integral parts of regulatory mechanisms that operate in all human cells. Impairing G protein function can affect a cell's response to hormonal signals, e.g., by interfering with intracellular metabolic pathways. This can cause development or maintenance of a wide variety of disease states. When functioning normally, G proteins act as essential parts of signal transducing mechanisms by which extracellular hormones and neurotransmitters convey their signals through the plasma membrane of the cell and thus elicit appropriate intracellular responses. These signal transducing mechanisms comprises three distinct components: 1) a receptor protein with an extracellular binding site specific for a given agonist or hormone; 2) a membrane-bound effector protein that when activated catalyzes the formation or facilitates the transport of an intracellular second messenger, such as adenylyl cyclase which converts ATP to cyclic AMP (cAMP); and 3) a protein which functions as a communicator between these two. 2 G proteins fulfill this function as communicator between receptor and effector proteins in the generation of intracellular responses to extracellular hormones and agonists. G proteins are composed of three polypeptide subunits: G alpha (or G , G beta (or G b ) and G gamma (or G g ). The G b and G g polypeptide subunits occur in living cells as a heterodimer, commonly referred to as a "bg" dimer. The conformation of these subunits and their degree of association with each other change during the signal transducing mechanism. These changes are associated with the hydrolysis of the nucleotide guanosine triphosphate (GTP) to form guanosine diphosphate (GDP) and free phosphate (GTPase activity). The binding sites for GTP and GDP, and the GTPase catalytic site, reside in the alpha subunit of the G protein. An example of a G protein cycle which occurs when a signal is conveyed across the cell membrane is as follows: In an unstimulated cell the G proteins are found in a resting state in which alpha, beta and gamma subunits are complexed together and GDP is bound to G a . The binding of an appropriate hormone or agonist to the receptor changes its conformation and causes it to activate the G protein by displacing GDP and allowing GTP to bind. This is the rate-limiting step in the G protein cycle. When GTP is bound to G a it may dissociate from bg and is able to bind to, and activate, adenylate cyclase, which releases cAMP into the cytoplasm. GTP is then hydrolysed to GDP G a and the cycle is complete. A series of complex interactions has evolved to allow signal amplification, such that a single hormone-receptor complex can trigger the production of several hundred second messenger molecules, such as cAMP. cAMP is a potent second messenger that binds to and activates protein kinase A (PKA). PKA was first shown to play a role in glycogen metabolism and is now known to influence a variety of processes, including transcription. This system also allows several different receptors to interact with a signal-generating enzyme. The receptors can activate the enzyme or inhibit it. For example, distinct alpha subunits G sa (stimulatory) and G ia (inhibitory) combine with the bg complex to form stimulatory or inhibitory G proteins. An example of a receptor that interacts with G { to lower the concentration of cAMP is the alpha 2-adrenergic receptor. Integration of signals from G s and G allows the level of cAMP in the cell to be fine-tuned in response to several different extracellular agonists. 3 Although G proteins were first identified and characterized in relation to the adenylyl cyclase system discussed above, it is now known that they are involved in many aspects of cell signaling. In particular, certain G proteins act in signal transducing pathways that activate phospholipase C. This enzyme catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP 2 ) to form diacylglycerol (DG) and inositol 1,4,5-triphosphate (IP 3 ). DG activates protein kinase C (PKC) which phosphorylates a certain sub-set of cellular proteins and modulates their activity. For example, PKC is important in controlling intracellular pH and in transcriptional activation of specific genes. IP 3 is a small water-soluble molecule that causes the release of calcium ions (Ca 2+ ) from intracellular stores. Ca 2+ is a potent intracellular messenger in several metabolic and homeostatic pathways. Many drugs are currently directed at hormone receptors. Examples include beta-adrenergic agents used in the treatment of asthma, and "beta-blockers" used in the treatment of high blood pressure. Assays for chemical compounds that act at particular G protein coupled receptors have typically been based on the use of radioligands, where either the drug of interest is radiolabeled and its binding to receptor directly assayed, or the ability of a compound of interest to displace a known radioligand from a receptor of interest is assayed. Radioligand binding assays, however, use dangerous and expensive radioisotopes, and require disposal of radioactive reagents and supplies. Also, these assays are not as amenable to high- throughput systems as are assays which monitor intracellular processes such as calcium release. Various methods have been developed to assay for receptor/ligand interactions without using radioactive reagents. For example, to assay G protein coupled signal transduction pathways that involve the release of intracellular calcium stores, direct detection methods have been developed that precipitate calcium with alizarin sulfonate. Receptors are normally present in very low numbers on the surfaces of cells that are useful in such assays. Therefore, when performing receptor activation assays it is common to first overexpress the receptor of interest by introducing into cells DNA which is capable of expressing the receptor. However, merely overexpressing the desired receptor may not allow generation of sufficient signal. For example, when the receptor is activated, it may 4 not transduce sufficient intracellular calcium to allow unambiguous detection. This problem has been found by the present inventors to be particularly present with respect to detection of intracellular calcium release associated with the activation of G, coupled receptors. Thus, when G, coupled receptors are overexpressed in cells, the calcium release achieved by exposure of the cells to receptor agonist or antagonist compounds can be too low for reliable measurement, i.e., the resulting signal strength may be too low for an efficient assay. Thus, there is a need for a method to increase the second messenger signal strength generated by agonist binding to receptor-overexpressing cells. The signal generated by agonist binding must be sufficiently robust that a decrease in signal, e.g., in response to antagonist binding, is detectable. SUMMARY OF THE INVENTION It has been determined that expression of transfected DNA encoding a G ιa protein subunit that couples to a co-expressed receptor that couples to a G, protein will obviate the "signal strength" problem referred to above, and will produce a significant and reproducible intracellular calcium signal that can be reliably detected. In one aspect, the invention relates to a method for assaying a test compound for its effect on a G, protein coupled receptor. The method involves contacting a cell with the test compound and assaying the cell for cytoplasmic calcium concentration. According to the invention, the cell employed in such an assay has been transfected with a gene encoding a G, protein coupled receptor and with a gene coding for a G ιa protein capable of coupling to the G, protein coupled receptor to increase cytoplasmic calcium upon binding of an agonist to the G, protein coupled receptor. In another aspect, the present invention relates to a cell useful for high- or low-throughput assays to determine if a compound binds to a ^ protein coupled receptor, the cell comprising transfected DNA which expresses a G, coupled receptor, transfected DNA which expresses a G ιa protein subunit, and an intracellular calcium release mechanism which produces a detectable signal as measurable by fluorescence of a fluorophore in response to agonist compound binding to the receptor when the G, protein coupled receptor is coexpressed with the G ιa protein subunit. In yet another aspect, the invention relates to a method for producing a cell for detecting compounds which bind to a G, protein coupled receptor which 5 comprises the steps of transfecting a cell with a gene which codes for a G, protein coupled receptor, transfecting the cell with a gene which codes for a G ιa protein capable of coupling to the receptor, and culturing the cell in medium under conditions in which the G ιa protein and the ^ protein coupled receptor are co-expressed in the cell. BRIEF DESCRIPTION OF THE DRAWINGS Figure la is a depiction of the pHEBo vector. Figure lb is a depiction of the p394 vector. Figure lc is a depiction of the pcmvmcsl vector. Figure Id is a depiction of the pcDM8 vector. Figure le is a depiction of the pm3ar vector. Figure If is a depiction of the pm3CCR3 vector. Figure lg is a schematic showing the modification of the CCR3 gene by the addition of a signal sequence coding region. Figure lh is a depiction of the pm3CCR3sp vector. Figure 2a is a depiction of the pE3 vector. Figure 2b is a depiction of the pE3delta vector. Figure 2c is a depiction of the pPur vector. Figure 2d is a depiction of the pE3pur vector. Figure 2e is a depiction of the pEpurGia2 vector. Figure 3 is the nucleotide sequence of the pCEP4 vector. Figure 4 is the nucleotide sequence of the pCDM8 vector. Figure 5 is the. nucleotide sequence of the pBSIISK+ vector. Figure 6 is the nucleotide sequence of the pPur vector. Figure 7 is a bar graph illustrating the stability of the Kd for agonist in CCR3 receptor and CCR3 receptor/G ιa2 protein transfected cells. Figure 8 is a bar graph illustrating the stability of the receptor number per cell in CCR3 receptor and CCR3 receptor/G ιa2 protein transfected cells. Figure 9 is a bar graph illustrating the increases in calcium mobilization in response to eotaxin either in cells transfected with the CCR3 receptor alone or in cells cotransfected with the CCR3 receptor and G ιa2 protein. Figure 10 is a bar graph illustrating the increases in calcium mobilization in response to nociceptin either in cells transfected with the nociceptin 6 receptor alone or in cells cotransfected with the nociceptin receptor and G ιa2 protein. Figure 11 is a graph representing a time course illustrating the increase in the concentration of intracellular calcium in response to the CCR2 agonist MCP-1 either in cells transfected with the CCR2 receptor alone or in cells cotransfected with the CCR2 receptor and G ιa2 protein. Figure 12 is graph showing the dose-response relationship for increases in cytoplasmic calcium as a result of exposure of cells to interleukin 8 either in cells transfected with the interleukin 8 receptor type B alone or in cells cotransfected with the interleukin receptor type B and G ιa2 protein. DETAILED DESCRIPTION OF THE INVENTION All patents, patent applications, and publications referred to herein are hereby incorporated by reference in their entirety. In case of a conflict in description or terminology, the present disclosure is intended to control. Definitions: "G, protein" as used herein refers to the heterotrimeric guanine nucleotide binding proteins G d , G^, and G l3 , including those from any animal species (e.g. mouse), and derivatives having mutated sequences such as G ιp2 . "Transfecting" as used herein means to introduce exogenous DNA into a cell. "Codes for" as used herein means the property of a DNA polynucleotide to be transcribed by an RNA polymerase into messenger RNA, which messenger RNA can in turn be translated into a polypeptide. The polypeptide so produced is said to be "coded for" by the DNA polynucleotide. G protein "coupling" to a receptor as used herein means the activation of a guanine nucleotide binding protein by the interaction of a cell surface receptor with an agonist for that receptor. "Culturing" as used herein means the incubation of cells in a medium sufficient for the maintenance of cell division and cellular physiological processes. "Co-expressed" as used herein means that at least two proteins are synthesized in a cell as a result of the introduction into the cell of DNA foreign to the cell. "Cellular response" as used herein means the response of a cell to the activation of a G protein by an agonist-bound receptor, or the response of a cell to the 7 presence of a receptor antagonist, and includes second messenger responses such as the opening or closing of ionic channels, such as calcium or potassium channels, the activation or inhibition of adenylyl cyclase, which catalyzes the conversion of ATP to cyclic AMP, and the activation of phospholipase C, which cleaves phosphatidylinositol 4,5 bisphosphate into diacylglycerol and inositol triphosphate (IP 3 ). "Native DNA" of a cell or cell line is the DNA complement of a defined cell or cell line prior to the introduction, by any means, of exogenous DNA into the cell or cell line. "Integrated" as used herein with regard to DNA refers to DNA that has been transfected into a cell which has been incorporated into the native DNA of a cell. "Stably transfected" as used herein means the introduction into and maintenance of exogenous DNA into a cell or cell line by integration into the host chromosome or by episomal transfection for at least 2 weeks and preferably more than 4 months. "Transiently transfected" as used herein means the introduction into and maintenance of exogenous DNA in a cell or cell line for a limited period of time. If the DNA is derived from an integrating construct, then transience is defined as 0 to 5 days post transfection or until detectable signal has faded into insignificance. If the DNA is derived from a replicating, episomal construct, then transience is defined as 0 to 21 days post transfection, or until detectable signal has faded into insignificance. A detectable signal can be the direct detection of the transfected DNA, for example by Southern blotting or PCR, or detection of an RNA transcribed from the DNA, or detection of a protein expressed by the DNA. A "DNA construct" as used herein means a polynucleotide which contains an open reading frame which encodes a protein, and includes any promoter, transcription initiation, transcription termination, or other nucleotide sequences which might facilitate expression of the encoded protein. An "intracellular calcium release mechanism" as used herein means any combination of cellular proteins which, when activated, function to cause the release of calcium ions from intracellular stores into the cytoplasm of the cell. G; protein coupled receptors, such as the C-C chemokine receptor 3 (CCR3), C-C chemokine receptor 2 (CCR2), interleukin 8 receptor type B (CXCR2), and nociceptin receptor (NociR), must physically couple to G; proteins in order to 8 transduce extracellular stimuli into intracellular signals that lead to functional responses. We have developed an assay for detecting agonists and antagonists of G, protein coupled receptors. The assay is particularly useful in high throughput screening to determine compounds that are useful as drug candidates. When expressed from exogenously introduced DNA constructs, G, protein coupled receptors can be expressed at low levels on the surface of the transfected cells; they may also overwhelm the endogenous cellular mechanism for transducing extracellular signals into intracellular responses. The signals generated by activation of such expressed receptors can be weak. We have determined that when performing assays relying on mobilization of calcium from intracellular stores, weakness in signal strength can be obviated by transfecting cells which express G, protein coupled receptors with a DNA construct which encodes a G ιa protein subunit capable of coupling to the receptor. This can be done, for example, by cotransfecting cells with separate constructs encoding the G, protein coupled receptor and G ιa protein subunit, or by transfecting a single construct which encodes both a G, protein coupled receptor and a G ιa protein subunit. Coexpression of the G ιa subunit has been determined to have a positive effect on intracellular calcium mobilization. It has been determined in particular that G ιa protein subunits transduce signal generated by G, coupled receptors to release intracellular calcium stores. It is known that G protein bg dimers are required in the signal transduction pathway from G, coupled receptors to the activation of phospholipase C (which ultimately results in the release of intracellular calcium stores). See, e.g. , Wu, D. et al., Science 261: 101 (1993); Slepak, V.Z. et al. , J. Biol. Chem. 270:4037 (1995); and Arai, H. et al., Proc. Natl. Acad. Sci. 94: 14495 (1997). We have determined that expression of G ιa protein subunits can act to stimulate calcium release in response to receptor activation. Furthermore, expression of bg dimers or phospholipase C b (PLCb) is not required. DNA, VECTORS, and HOST CELLS In practicing the present invention, many conventional techniques in molecular biology, microbiology, and recombinant DNA are used. Such techniques are well known and are explained fully in, for example, Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor 9 Laboratory Press, Cold Spring Harbor, New York; DNA Cloning: A Practical Approach, Volumes I and II, 1985 (D.N. Glover ed.); Oligonucleotide Synthesis, 1984, (M.L. Gait ed.); Nucleic Acid Hybridization, 1985, (Hames and Higgins); Transcription and Translation, 1984 (Hames and Higgins eds.); Animal Cell Culture, 1986 (R.I. Freshney ed.); Immobilized Cells and Enzymes, 1986 (IRL Press); Perbal, 1984, A Practical Guide to Molecular Cloning; the series, Methods in Enzymology (Academic Press, Inc.); Gene Transfer Vectors for Mammalian Cells, 1987 (J. H. Miller and M. P. Calos eds. , Cold Spring Harbor Laboratory); and Methods in Enzymology Vol. 154 and Vol. 155 (Wu and Grossman, and Wu, eds. , respectively). Insertion of nucleic acids (typically DNAs) encoding the receptor and G ιa polypeptides into a vector to create a DNA construct for transfection is easily accomplished when the termini of both the DNAs and the vector comprise compatible restriction sites. If this cannot be done, it may be necessary to modify the termini of the DNAs and/or vector by digesting back single-stranded DNA overhangs generated by restriction endonuclease cleavage to produce blunt ends, or to achieve the same result by filling in the single-stranded termini with an appropriate DNA polymerase. Alternatively, any restriction site desired may be produced, e.g., by ligating nucleotide sequences (linkers) onto the termini. Such linkers may comprise specific oligonucleotide sequences that define desired restriction sites. Restriction sites can also be generated by the use of the polymerase chain reaction (PCR). See, e.g., Saiki et al., 1988, Science 239:48. The cleaved vector and the DNA fragments may also be modified if required by homopolymeric tailing. Nucleic acids utilized in the invention may be isolated directly from well-known cells. Alternatively, the polymerase chain reaction (PCR) method can be used to produce the nucleic acids of the invention, using either chemically synthesized strands or genomic material as templates. Primers used for PCR can be synthesized using the sequence information provided herein and can further be designed to introduce appropriate new restriction sites, if desirable, to facilitate incorporation into a given vector for recombinant expression. A clone containing DNA expressing G ιa2 is available from the American Type Culture Collection, Rockville, MD, Cat. No. 63311, and the sequence of G ιa2 protein is available from Genbank, accession number Ml 3963. The sequence of a G ιal protein is available from Genbank, accession number M 17219, and the sequence of a G ιa3 protein is also available from Genbank, accession 10 number M20597. A clone containing DNA expressing G, p2 is available from the American Type Culture Collection, Rockville, MD, Cat. No. 63312; the DNA has the sequence G ιa2 Q205L. The nucleic acids employed in the present invention may be flanked by native regulatory sequences, i.e. , those that are found associated with the relevant gene in the genome of the organism from which the gene is isolated, or may be associated with heterologous sequences, including promoters, enhancers, response elements, signal sequences, polyadenylation sequences, introns, 5'- and 3'- noncoding regions, and the like. The nucleic acids may also be modified by many means known in the art. Non-limiting examples of such modifications include methylation, "caps", substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages (e.g. , methyl phosphonates, phosphotriesters, phosphoroamidates, carbamates, etc.) and with charged linkages (e.g. , phosphorothioates, phosphorodithioates, etc.). The invention employs nucleic acid vectors, or DNA constructs comprising nucleic acid sequences which code for the G ιa protein or G, coupled receptors. It is understood that if desired, functional derivatives or fragments thereof may be employed to the same effect. A large number of well-known vectors can be used in the invention for expression in a variety of eukaryotic hosts. For example, the G ιa protein or G, coupled receptors may be expressed by transfecting known mammalian expression vectors, such as vectors available commercially from, e.g. , Invitrogen Corporation, Carlsbad, CA, such as pcDNAl.l for transient transfection, and pcDNA3.1, pcDNA3.1/zeo or pcDNA3.1/hyg, pRc/RSV or pRc/CMV2 for stable transfection, employing appropriate eukaryotic host cells, and using methods disclosed herein or otherwise known to those skilled in this art. Recombinant cloning vectors employed in the invention can include one or more replication systems for cloning or expression, one or more markers for selection in the host, e.g. antibiotic resistance, and one or more expression cassettes. The inserted G ιa protein and G, coupled receptor coding sequences may be synthesized by standard methods, isolated from natural sources, or prepared as hybrids. Ligation of the G Ia protein and G, coupled receptor coding sequences to transcriptional regulatory elements and/or to other amino acid coding sequences is achieved by known 11 methods. Suitable host cells may be transformed/transfected/infected as appropriate by any suitable method including electroporation, CaCl 2 mediated DNA uptake, microinjection, and microprojectile based transfection. A large number of transcription initiation and termination regulatory regions that can be employed in the invention have been isolated by those skilled in this art and shown to be effective in the transcription and translation of heterologous proteins in eukaryotic host cells. These regions, methods of isolating them and ways to manipulate them are well-known in the art. Advantageously, vectors and DNA constructs employed in the invention also include a transcription regulatory element (i.e., a promoter) operably linked to the nucleotide sequence encoding the protein to be expressed. The promoter may optionally contain operator portions and/or ribosome binding sites. Suitable promoters for mammalian cells include without limitation viral promoters such as those from Epstein-Barr Virus (EBV), Simian Virus 40 (SV40), Rous sarcoma virus (RSV), adeno virus (ADV), and bovine papiUoma virus (BPV). Mammalian cells may also require terminator sequences and poly(A) addition sequences. Enhancer sequences, which increase expression, may also be included. Sequences which cause amplification of the gene may also be desirable. These sequences are well described in the art. Nucleic acids encoding G ιa or G, coupled receptor polypeptides may also be introduced into cells by known recombination methods. For example, such nucleic acids can be introduced into a cell to effect homologous recombination at the site of a corresponding endogenous gene or a sequence with substantial identity to the gene. Other known recombination-based methods such as nonhomologous recombination or deletion of endogenous genes by homologous recombination may also be used. Preferably, separate episomal plasmids are used for expression of the G, coupled receptor and the G ιa protein subunit. Each such episome preferably contains its own selectable marker. The two episomes may be co-transfected simultaneously into the same cell to produce a pool of stably transformed cells available for use in high-throughput screening assays. Such cells are advantageously obtained within about 2 weeks. Transformation methods in which either the gene encoding the G, coupled receptor or the gene encoding the G ιa subunit (or both) is integrated into the host nuclear material are less preferred, as the time required to obtain a cell line in this 12 manner which stably expresses either protein is normally from three to six months. Using the preferred episomal expression system of the invention, the need for clonal selection of stably transfected cells is eliminated, assay able cell lines are generated in weeks rather than months, and the cellular response achievable in response to receptor activation is significantly enhanced. The preferred episomal expression system of the invention employs episomes bearing an EBV origin of replication in a permissive cell type expressing the EBNAl protein for recombinant receptor binding assays. Primate and canine cell lines are preferred as host cells. Rodent cells are not preferred since they are not permissive for EBNAl /EBV oriP interactions, i.e. , rodent cells do not permit replication of EBV oriP based vectors. HEK-293 cells are particularly preferred and are available from the American Type Culture Collection (ATCC), Rockville, MD, Accession Number CRL-1573. HEK-293 cells that constitutively express EBNAl are most preferred, and are commercially available from Invitrogen Corporation, Carlsbad, CA. If desired, episomes can be used for the construction of integratively stable cell lines that express EBNAl. That is, the episomes of the invention can be used to transfect cells, and rather than replicate independently, the genes encoded on the episomes can be integrated into the chromosomes of the host cell, thereby allowing replication along with the host cell's DNA. If episomes are employed which also express the EBNAl protein, then any permissive cell line can be used to practice the invention, regardless of whether or not it pre-expresses EBNAl . The preferred episomally co-transfected cell lines of the invention remain stably transfected for at least 5 months after transfection, preferably as demonstrated by ligand-induced cellular responses, northern blot analysis of steady state RNA levels (encoding receptor and G protein), and western blot analysis of G protein levels. In order to detect the release of intracellular calcium stores in response to stimulation of G s coupled receptors by agonists, or the inhibition of such release due to binding of antagonists to Gj coupled receptors, both direct and indirect measurements can be used. Such methods are well-known in this art. For example, direct detection methods are well-known that precipitate calcium with alizarin sulfonate. Other well-known direct detection methods use photoproteins that fluoresce 13 when bound to calcium, such as aequeorin and obelion. Recently, non-protein fluorescent indicators of calcium release have been developed for use in direct detection; these include Fura-2/AM, Indo-1/AM, and Fluo-3/AM and their derivatives. Such fluorescent probes are commercially available, and can be obtained from Molecular Probes, Eugene, OR; Teflabs, Texas; and Sigma Chemical Co. , St. Louis, MO. Other known methods for direct detection of calcium use metallochromic indicators such as murexide, arsenazo III, and antipyrylazo III. Calcium release can be indirectly measured using patch clamps (which record calcium release in single cells), mini/microelectrodes, and vibrating calcium electrodes. Confocal microscopy permits sensitive visual detection of fluorescence due to calcium. Methods of screening using confocal microscopy are described in U.S. patent application Serial No. 08/868,280 filed June 3, 1997. The method of the invention can be carried out as part of a high throughput screening of a library of compounds for binding to receptor. In one embodiment of the invention, the method is carried out with a plurality of compounds to be screened, preferably at least about 96 compounds, such as when using a 96 well microtitre plate. Such assays can also be performed in the 1536 well plate described in U.S. patent application serial no. 60/037,636, filed February 18, 1997. The library of compounds to be screened can be quite large, e.g. , containing more than 100,000 compounds. It is preferred that the compounds assayed in the high throughput method be derived from combinatorial libraries on polymer beads. By synthesizing sufficient compound on each bead for a few assays, compound handling is reduced or eliminated. Preferably, the library compounds are eluted from the beads and evaporated to dryness in microtiter plates in preparation for the assay. Compounds on beads can be released by photocleavage, or another type of cleavage. Cleavage of photocleavable linkers is preferred. Such linkers, and methods for their cleavage, are described in Barany et al. (1985) J. Am. Chem. Soc. 107:4936. Examples of other linkers and the relevant cleavage reagents are described in WO 94/08051. Using combinatorial libraries prepared on beads, the identity of active 14 compounds is preferably determined using the encoding system described in WO 94/08051 and in WO 95/30642. In this system, chemical tags encoding the identities of the compounds are applied to the solid supports. The identity of the compound on a given support can be determined by detaching the chemical tags from the support, identifying the tags by, e.g. , gas chromatography, and correlating the identities of tags with the identity of the compound. Once an active compound is identified, the corresponding bead (which had contained the compound) can be examined, and the identity of the compound determined by releasing the tags and decoding by this method. The following examples are intended to illustrate the invention only, and are not intended to be limiting in any way. Many variations and adaptations of the present invention will be apparent to those of ordinary skill in the art, and these are intended to be included within the scope of the invention. EXAMPLE 1: CONSTRUCTION OF EPISOMAL EXPRESSION VECTORS A. Construction of pHEBO Vector The pHEBo vector was made using commercially available vectors. The sequence of vector pBR322 (Genbank accession number synpbr322) from nucleotide 1 to nucleotide 772 was ligated to the nucleotide sequence of vector pCEP4, SEQ ID NO: 1, Figure 3, from position 8146 to 10376 (Invitrogen, Carlsbad, CA, Cat. No. V004-50). To this construct was ligated pCEP4 nucleotides 1333 to 5500. Prior to ligation, fragments were PCR amplified or joined using preexisting restriction sites. The resulting plasmid contained the Epstein Barr Virus (EBV) origin of replication (oriP), a hygromycin resistance marker (hyg) transcribed from the minimal Herpes Simplex Virus (HSV) thymidine kinase (tk) promoter, and was terminated with the tk poly adenylation signal (poly (A)), in vector pBR322. The pHEBo vector is shown schematically in Figure la. B. Construction of pcmvmcsl Vector Vector p394 was constructed according to Colberg-Poley, A.M. et al. / Virol. 1992 Jan; 66(1): 95-105. Briefly, the vector can be made by cloning the CMV IE promoter (which can be obtained from vector pCEP4, SEQ ID NO: 1, nucleotide 1132 to 474) into the EcoRV site of pBSIISK(+) SEQ ID NO: 6. Oligonucleotides 5'- ATATCATAATATGTACATTTATATTG-3', SEQ ID NO: 13 and 5'- TCGCGACGTCTCCGTGTAGGCGATCTGACGGTTCACTAAAC-3', SEQ ID NO: 15 14 were used to amplify the promoter. The SV40 poly (A) signal, which can be obtained, e.g. , from pCEP4, SEQ ID NO: 1 (from the native BsaBI site at nucleotide 176 to the native BamHI site at position 412) was cloned into the Smal and BamHI sites of pBSSK(+)-CMVIE. Using the remaining EcoRI and PstI sites in between the CMV promoter and SV40 poly (A), a multiclomng site was added using oligonucleotides: 5'-AATTCGCGACGCGTGATATCTGCAGGCCTAGATCTCTAGATAAGTAAT GATCATGCA-3', SEQ ID NO: 15 and 5 '-TGATCATTACTTATCTAGAGATCTAGGCCTGCAGATATCACGCGTCGCG-3 ' , SEQ ID NO: 2, yielding vector ρ394. Vector p394 (Figure lb), was cleaved with Hindlll and BamHI to yield a 1.3 kb Hindlll - BamHI fragment containing the cytomegalovirus immediate early promoter (CMV), a multicloning site region (mcs), and the SV40 poly (A) region. This fragment, which comprises an "expression cassette" was cloned into the Hindlll and BamHI sites of pHEBo to yield pcmvmcsl (Figure lc). The mcs contains the following restriction enzyme sites: Esp3I, EcoRI, Nrul, Mlul, EcoRV, PstI, StuI, Bglll. The mcs in vector pcmvmcsl was replaced with the following sites: Esp3I, Agel, StuI, Kpnl, Avrll, Xhol, by a synthetic oligonucleotide linker that contained overhangs compatible with the Esp3I and Bglll sites. The Bglll site was not recreated by the oligonucleotide linker (Figure 2e). This vector was designated pcmvmcs3. C. Construction of pm3ar Vector An intron (called IVS or "intervening sequence") was added to the expression cassette (defined herein as the CMVIE-mcs-poly(A) containing nucleotides) as follows. A Xhol - BamHI fragment containing the SV40 early intron and poly (A) signals was excised from vector pCDM8 (Invitrogen, Carlsbad, CA; Figures Id and 4), SEQ ID NO: 3. The poly(A)-containing fragment was removed from vector pcmvmcs3 by digestion with restriction enzymes Xhol and BamHI, and the Xhol- BamHI fragment from pCDM8 was added, generating vector pm3ar (Figure le). D. CCR3 Expression Vector An episomal vector which codes for the C-C chemokine receptor 3 ("CCR3") was constructed. The coding region for the receptor was obtained by PCR amplification of genomic DNA, using the oligonucleotide 5'- 16 GTGAAATGACAACCTCACTAGATACAG-3', SEQ ID NO: 4 as the sense primer, and 5'-CTGACCTAAAACACAATAGAGAGT-3', SEQ ID NO: 5, as the antisense primer. The PCR fragment obtained was cloned into the EcoRV site of pBSIISK+ (Figure 5)(a Bluescript vector commercially available from Stratagene, La Jolla, CA, Stratagene Cat. No. 212205, Genbank accession number 52325), SEQ ID NO. 6. The coding region was excised from pBSIISK+ using the restriction enzymes Spel and Nsil, and the fragment containing DNA coding for CCR3 was cloned into the Avrll and Sse8387I sites of vector pm3ar (Figure le) to generate episomal expression construct pm3CCR3 (Figure If). A hydrophobic signal sequence was added to the CCR3 coding sequence by PCR (see Figure lg). Vector pm3CCR3 was used as a template and oligonucleotide 144, 5'-TGTCGATTGTCAGCAGGATTATG-3' SEQ ID NO: 7 (which begins at nucleotide +390 and maps 3" to the unique Bglll restriction site on the vector) and oligonucleotide 143,5 '-GTTCTGTCTCTGCTGCCACTG CTCGAGGCTCAAACAACCTCACTAGATACAGTTGAG-3', SEQ ID NO: 8 (which overlaps the CCR3 coding sequence and contains a long tail encoding approximately two-thirds of the hydrophobic signal sequence) were used as primers. The resulting 428 base pair fragment was then used as a template for PCR, using oligonucleotide 144, SEQ ID NO: 7 and oligonucleotide 142, GAGCAGCCGGCACC ACCATGGCTCTGTCTTGGGTTCTGACTGTTCTGTCTCTGCTGCCACTG, SEQ ID NO: 9 (which encodes the remainder of the hydrophobic signal sequence and contains a Kozak consensus sequence for efficient initiation of translation). The resulting 461 base pair fragment was digested with NgoMI and Bglll and cloned into the Avrll and Bglll sites of pm3CCR3 to generate expression vector pm3CCR3sp (Figure lh). E. Construction of pE3 Vector Vector pm3ar (Figure le) was altered to provide an additional set of cloning sites immediately upstream from the CMVIE promoter. The new sites were added using a synthetic oligonucleotide linker 5'- CGATCACGTGCAGCTGAGATCTA-3', SEQ ID NO: 10, that contained the restriction sites, Clal, Ascl, BssHII, Pad, Hindlll and overhangs compatible with the Clal and Hindlll sites of pm3ar. The new vector was designated pE3 (Figure 2a). F. Construction of pE3delta Vector 17 Vector pE3delta (Figure 2b) was generated by the digestion of vector pE3 with BstBI and BspLUllI to remove the hygromycin coding region. The hygromycin coding region was replaced with a synthetic oligonucleotide linker 5'- CATGTAGATCTCAGCTGCACGTGAT-3', SEQ ID NO: 11 containing multiple cloning sites. G. Construction of pE3pur Vector Vector pE3pur (Figure 2d) was constructed by the digestion of vector pE3delta with PvuII and BspLUllI followed by ligation to a PvuII - Bgllll fragment (Figure 2c) obtained from vector pPur (Clontech, Cat. No. 6156-1, Genbank accession number U07648, SEQ ID NO: 12, Figure 6). The PvuII - Bgllll fragment from vector pPur contains the SV40 promoter, a puromycin resistance gene, and an SV40 poly (A) tail. H. G ia2 Expression Vector Vector pBN31, which contains the wildtype sequence for murine G ia2 cloned into the EcoRI site of vector pCDNAI, was obtained from the American Type Culture Collection (ATCC), Cat. No. 63311, Rockville, MD. pE3pur vector (Figure 2d) was digested with Kpnl and Xhol, which correspond to restriction sites found within the multicloning regions at the 5' and 3' ends, respectively, of the G ia2 coding region. The vector obtained from the ATCC was also digested with Kpnl and Xhol, and a fragment containing the G ia2 coding region was excised. This fragment was cloned into the Kpnl and Xhol sites of vector pE3pur, to produce vector pEpurGia2 (Figure 2e). This vector was used without further modification to transfect cells. EXAMPLE 2: TRANSFECTION OF CELLS AND MAINTENANCE OF STABLY TRANSFECTED CELL LINES 293E cells (HEK-293 cells which constitutively express the Epstein-Barr virus nuclear antigen- 1, commercially available from Invitrogen Corp., Carlsbad, CA, cat. no. R620-07) were transfected using the calcium phosphate or lipofectamine procedures as described in Sambrook et al. , (1989) "Molecular Cloning: A Laboratory Manual," Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 1633- 1634. T75 flasks containing approximately 1 x 10° 293E cells were transfected with plasmid p3ARccr3 with or without cotransfection with pEpurGia2. 5 mg of each plasmid was used in the transfection reaction, with 62 ml of 2 M CaCl 2 in enough 18 water to achieve a final volume of 500 ml. To this solution was added 500 ml of HEPES-buffered saline ("HBS") and the entire 1 ml of solution was added directly to the T75 culture medium (12 ml of Dulbecco's Modified Eagle Medium, "DMEM", supplemented with 10% fetal bovine serum, penicillin 100 units/ml, streptomycin 100 mg/ml, glutamine 2 mM, hereinafter called "complete DMEM"). The transfection mix was allowed to remain on the cells for 48 hours at which time the cells were washed once with phosphate buffered saline and re-fed selective media (complete DMEM supplemented with 1 mg/ml puromycin and 250 mg/ml hygromycin, hereinafter called "selective media"). The selective media was changed at day 5 post- transfection (i.e. , day 5 after the transfection mix was removed) and again when the cells approached confluence, at which time cells were routinely split, i.e. , "passed" between 1:4 and 1:50 in fresh selective media as needed. Frozen stocks of cells were made at cell passage 3. EXAMPLE 3: STABILITY OF EXPRESSION FROM EPISOMES Cells expressing either the CCR3 receptor, or both the CCR3 receptor and G ia2 protein, generated according to Example 2, were assayed for agonist binding characteristics. The cells were incubated in 125 I-eotaxin at concentrations ranging from 45 pM to 300 nM. Specific binding was determined at each concentration, as was the maximum binding for a given number of cells. Based on these values, the Kd for eotaxin was determined at the end of 1 to 5 months after vector transfection. As can be seen from Figure 7, the Kd for the cells was stable, remaining between 0.2 and 0.3 nM for the entire five months for the cotransfected cells, and between 0.2 and 0.5 nM for the cells containing CCR3 receptors which were not coexpressed with G ia2 . In addition to the stability observed for Kd values, the total receptor number was also stable over the five month period, regardless of whether the CCR3 receptor was coexpressed with G ia2 protein or not. In particular, Figure 8 shows that the receptor number in the singly transfected and cotransfected cells was approximately equal and stable over the entire 5 month assay period, at about 20,000 receptors per cell. The stability of the Kd of the receptors for agonist over time is important, as variations in Kd, particularly increases in Kd, could lead to false negative responses in assays for compounds that bind to receptors. 19 EXAMPLE 4: ASSAYS FOR CALCIUM MOBILIZATION IN RESPONSE TO RECEPTOR BINDING OF AGONIST COMPOUNDS Assays were conducted utilizing the methods described in S.R. McColl and R.H. Naccache, Methods in Enzymology 288:301-309, 1997, "Calcium Mobilization Assays". Cell suspensions (10 7 cells/ml) were loaded with the fluorescent probe Fluo-3/AM (Teflabs, Texas) at 2 mM for 60 minutes at room temperature. The cells were washed, resuspended at 2-4 x 10 6 cells/ml in Hanks' Buffered Salt Solution, made 1.6 mM in CaCl 2 and 10 mM in HEPES (HBSS). Mock transfected cells, cells transfected with the CCR3 receptor only, cells transfected with G ia2 protein only, and cells cotransfected with CCR3 receptor and with G ia2 protein were then incubated in medium which comprised 100 nM of the CCR3 receptor agonist eotaxin. The cells' fluorescence was measured in a spectrofluorometer (Model SLM, Bowman Series 2, SLM-Aminco, Champagne, IL) at both the excitation wavelength, i.e. , 506 ran, and the emission wavelength, i.e. , 526 nm, for the chromophore. Internal calcium concentrations were calculated as described in Tsien, et al., J. Cell. Biol. 94:3325 (1982). Each assay was individually calibrated. Upon addition of receptor agonist, a nearly four-fold increase in fluorescence was detected in the cells which co-expressed the CCR3 receptor and G^ protein compared to the fluorescence achieved in the cells transfected with the CCR3 receptor alone (Figure 9). No calcium increases were observed in mock-transfected cells or in cells transfected with the G-proteins alone upon stimulation with eotaxin. The data demonstrate that the episomally expressed receptor/G-protein alpha subunit signal transduction apparatus is useful as early as two weeks post transfection, and is stable for at least 20 weeks. A similar experiment was performed using the nociceptin receptor. The results shown in Figure 10 demonstrate that upon addition of nociceptin receptor agonist, a two-fold increase in fluorescence was detected in the cells which coexpressed the nociceptin receptor and G ia2 protein compared to the fluorescence achieved in the cells transfected with the nociceptin receptor alone. Again, receptor and G protein alpha subunit expression from episomes provided for readily assay able calcium responses in as little as two weeks. Figure 11 shows the increase in calcium flux that can be obtained in cells cotransfected with the CCR2 receptor and G ia2 relative to the calcium release 20 obtainable in cells transfected with only the CCR2 receptor in response to the chemokine MCP-1 (30 nM). The experiment was performed 2 months after transfection or cotransfection of cells. As can be seen from Figure 11, calcium release in cotransfected cells in response to exposure to CCR2 agonist MCP-1 was significantly greater than in cells which only expressed the CCR2 receptor. Calcium release in response to increasing concentrations of interleukin 8 was evaluated in cells expressing either the interleukin 8 receptor type B alone, or the interleukin 8 receptor type B coexpressed with G ia2 . The cells had been transfected 1 month prior to the assay. As can be seen from the data presented in Figure 12, there was an increase in the amount of calcium released from the cotransfected cells relative to the calcium released by the cells which were transfected only with the interleukin 8 receptor type B. These data are consistent with those presented for the CCR3, CCR2, and nociceptin receptors. Thus, these data demonstrate that coexpression of Gj alpha proteins with Gj protein coupled receptors provides for consistent increases in calcium signaling, allowing for more sensitive and reliable assays for receptor binding compounds, i.e., agonists and antagonists.

Claims: 21 WHAT IS CLAIMED IS: 1. A method for assaying a test compound for its effect on a G, protein coupled receptor which comprises the steps of: contacting said cell with a test compound; and assaying said cell for calcium concentration in the cytoplasm of said cell; said cell having been transfected with a gene encoding a G t protein coupled receptor and with a gene coding for G la protein capable of coupling to said G, protein coupled receptor to increase said cytoplasmic calcium upon binding of an agonist to said G, protein coupled receptor. 2. The method of claim 1 wherein said test compound is a receptor antagonist. 3. The method of claim 1 wherein said test compound is a receptor agonist. 4. The method of claim 1 wherein said gene coding for a G ιa protein codes for G ιa2 . 5. The method of claim 1 wherein said gene coding for a G ιa protein codes for G ml or G ιa3 . 6. The method of claim 1 wherein said gene coding for a G, protein coupled receptor and said gene coding for a G ιa protein capable of coupling to said receptor are expressed from separate DNA constructs. 7. The method of claim 1 wherein said gene coding for a G, protein coupled receptor and said gene coding for a G ιa protein capable of coupling to said receptor are expressed from a single DNA construct. 8. The method of claim 1 comprising direct measurement of said cytoplasmic calcium concentration within said cell. 22 9. The method of claim 1 comprising indirect measurement of said cytoplasmic calcium concentration within said cell. 10. The method of claim 1 wherein said gene coding for said G, protein coupled receptor is integrated in chromosomal DNA of said cell. 11. The method of claim 1 wherein said gene coding for said G, protein coupled receptor is expressed by a stably transfected episomal expression vector. 12. The method of claim 1 wherein said gene coding for said G, protein coupled receptor is expressed by a transiently transfected expression vector. 13. The method of claim 1 wherein said gene coding for said G ιa protein is integrated in said native DNA of said cell. 14. The method of claim 1 wherein said gene coding for said G ιa protein is expressed by a stably transfected episomal expression vector. 15. The method of claim 1 wherein said gene coding for said G ιa protein is expressed by a transiently transfected expression vector. 16. The method of claim 11 wherein said gene coding for said G ιa protein is expressed by a stably transfected episomal expression vector. 17. The method of claim 16 wherein said G, protein coupled receptor is selected from the group consisting of the C-C chemokine receptor 3, the C-C chemokine receptor 2, the interleukin 8 type B receptor, and the nociceptin receptor. 18. The method of claim 16 wherein said assaying comprises: detecting fluorescence produced by said cell; said cell having been loaded with a fluorophore that fluoresces in the presence of calcium. 23 19. The method of claim 18 wherein said fluorophore is Fura-2/AM, Indo-1/AM, or Fluo-3/AM. 20. The method of claim 1 wherein said cell has not also been transfected with genes encoding G lβ /G Ig dimer or phospholipase C β. 21. The method of claim 1 wherein said test compound is a receptor antagonist and is contacted with said cell in the presence of a receptor agonist, and wherein said step of contacting decreases said calcium concentration a compared with the calcium concentration of said cells contacted with said receptor agonist alone. 22. A cell useful for assaying a test compound for its effect on a G, protein coupled receptor, said cell comprising: transfected DNA which expresses a G, coupled receptor; transfected DNA which expresses a G ιa protein subunit; and an intracellular calcium release mechanism which produces a detectable signal as measured by fluorescence of a fluorophore in response to agonist compound binding to said receptor when said G, protein coupled receptor is coexpressed with said G ιa protein subunit. 23. The cell of claim 22 wherein said DNA which expresses a G, coupled receptor is exogenous DNA that has been stably integrated into chromosomal DNA of said cell. 24. The cell of claim 22 wherein said DNA which expresses a G, coupled receptor is contained in a stably transfected episomal expression vector. 25. The cell of claim 22 wherein said DNA which expresses a G, coupled receptor is contained in a transiently transfected episomal expression vector. 26. The cell of claim 22 wherein said DNA which expresses a G ιa protein subunit is exogenous DNA stably integrated into chromosomal DNA of said cell. 24 27. The cell of claim 22 wherein said DNA which expresses a G ιa protein subunit is contained in a stably transfected episomal expression vector. 28. The cell of claim 22 wherein said DNA which expresses a G ιa protein subunit is contained in a transiently transfected expression vector. 29. The cell of claim 22 wherein said G, protein coupled receptor is selected from the group consisting of the C-C chemokine receptor 3, the C-C chemokine receptor 2, the interleukin 8 type B receptor, and the nociceptin receptor. 30. The cell of claim 22 wherein said fluorophore is Fura-2/AM, Indo-1/AM, or Fluo-3/AM. 31. The cell of claim 22 which has not also been transfected with genes encoding G ώ /G, dimer or phospholipase C β. 32. A method for producing a cell for detecting compounds which bind to a G, protein coupled receptor which comprises the steps of: transfecting a cell with a gene which codes for a G, protein coupled receptor; transfecting said cell with a gene which codes for a G ιa protein capable of coupling to said receptor; and culturing said cell in medium under conditions in which the G ιa protein and the G, protein coupled receptor are co-expressed in said cell. 33. The method of claim 32 wherein said gene coding for a G, protein coupled receptor and said gene coding for a G ιa protein capable of coupling to said receptor are each expressed from a different DNA construct. 34. The method of claim 32 wherein said gene coding for a G la protein codes for a member selected from the group consisting of G ιa , and G^. 35. The method of claim 32 wherein said gene coding for a G ιa 25 protein codes for G ia2 .

Inventors: DAMAJ BASSAM B, HORLICK ROBERT A, ROBBINS ALAN K, DAMAJ, BASSAM, B., HORLICK, ROBERT, A., ROBBINS, ALAN, K.
Applicants: PHARMACOPEIA INC, PHARMACOPEIA, INC.
Application year: 1999
Main classification: G01N33
IPC codes: C07K14, C12N5, C12N15, C12Q1, G01N33